-
Mashup Score: 0Dr Ruben Mesa Discusses Balancing Treatment Access, Cost-Effectiveness for Patients With Rare Cancers - 6 month(s) ago
Ruben A. Mesa, MD, FACP, president and executive director of Atrium Health Levine Cancer Institute (LCI) and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, discusses how practices can improve access and affordability to treatments for rare cancers, such as myeloproliferative neoplasms.
Source: www.ajmc.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1
Abstract. Cardiovascular disease is a leading cause of death, morbidity, disability, and reduced health-related quality of life, as well as economic burden worl
Source: academic.oup.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Global perspectives on #HeartDisease #rehabilitation & secondary #prevention published by international #cardiovascular societies. #Nursing #Cardiology #Rehab #Challenges #Barriers #Costs #CostEffectiveness #morbidity #mortality #disability #HeartDisease https://t.co/r69RtJzB7q https://t.co/v9DKipF2rQ
-
-
Mashup Score: 0Cost–effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinoma | Immunotherapy - 9 month(s) ago
Objective: To evaluate the cost–effectiveness of serplulimab as first-line treatment for patients with advanced esophageal squamous cell carcinoma from the perspective of the Chinese healthcare system. Materials & methods: A partitioned survival model was created to evaluate costs and health outcomes. The model’s robustness was evaluated using one-way and probabilistic sensitivity analyses. Results: Serplulimab demonstrated an incremental cost–effectiveness ratio of $104,537.375/quality-adjusted life-year in the overall population group. Subgroup analysis showed that serplulimab had incremental cost–effectiveness ratios of $261,750.496/quality-adjusted life-year and $68,107.997/quality-adjusted life-year in the populations with PD-L1 1 ≤ combined positive score <10 and PD-L1 combined positive score ≥10, respectively. Conclusion: Incremental cost–effectiveness ratios of serplulimab therapy were found to exceed the willingness-to-pay threshold of $37,304.34. Thus, serplulimab is not cost
Source: www.futuremedicine.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Research study evaluates cost-effectiveness of serplulimab in advanced esophageal squamous cell carcinoma. Results suggest it may not be cost-effective compared to chemotherapy as first-line treatment. #EsophagealCancer #CostEffectiveness #Serplulimab https://t.co/EkRd32hKrj
-
-
Mashup Score: 3Biostatistician at Beth Israel Lahey Health - 1 year(s) ago
Learn more about applying for Biostatistician at Beth Israel Lahey Health
Source: jobs.bilh.orgCategories: Cardiologists, Latest HeadlinesTweet-
With @UMassChan regional medical school campus & Institute of Healthcare Delivery Science on the horizon, opportunities are endless If enthusiastic about #bigdata #Medicare #machinelearning #AI #sdoh #climate #costeffectiveness #clinicaltrials Apply https://t.co/u9rcNyJHsr
-
-
Mashup Score: 0When economy meets physiopathology: A novel cost-effectiveness model finally considers the cumulative effect of LDL cholesterol burden - 1 year(s) ago
Familial hypercholesterolemia (FH) is a prevalent hereditary autosomal dominant lipoprotein metabolic disorder marked by increased levels of LDL-cholesterol (LDL-C) and a higher risk of developing early cardiovascular disease [1]. Heterozygotic FH affects 1 in 250–300 individuals worldwide, and less than 1% of those subjects have been diagnosed to date [2,3].
Source: AtherosclerosisCategories: Cardiologists, Latest HeadlinesTweet-
When economy meets physiopathology: A novel #CostEffectiveness model finally considers the #cumulative effect of #LDL https://t.co/FG8PnMic5Q
-
-
Mashup Score: 3Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab - 1 year(s) ago
Immune checkpoint inhibitors have revolutionised cancer treatment by offering durable responses to many patients with solid and haematological cancers. The high prices and increasing use of immune checkpoint inhibitors put considerable strain on health-care budgets globally. This financial strain could jeopardise patients’ access to these anti-cancer therapies. However, substantial evidence…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New Personal View: Alternative #dosing strategies for #immunecheckpointinhibitors to improve #costeffectiveness: a special focus on #nivolumab and #pembrolizumab https://t.co/miiCbK3sun
-
-
Mashup Score: 3
This economic evaluation estimates the incremental cost per quit of adopting an intensive smoking cessation intervention among patients undergoing treatment at cancer care clinics, from a clinic perspective.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Cost-effectiveness of Implementing Smoking Cessation Interventions for Patients With #Cancer. https://t.co/3548jTCgb6 @JAMANetworkOpen @MGHCancerCenter @MonganInstitute @PsycholERPark @DrGKPerez #CancerResearch #CostEffectiveness https://t.co/0EUiSD2K9t
-
-
Mashup Score: 0
Purpose Adrenalectomies performed for the treatment of primary aldosteronism due to unilateral adenoma are traditionally confirmed with, and guided by, results from adrenal vein sampling (AVS). However, the usefulness of AVS at the expense of cost and complications is debated, and many institutions have independent protocols that use AVS to varying degrees. Methods Cost-effectiveness of AVS- vs…
Source: SpringerLinkCategories: Hem/Oncs, Latest HeadlinesTweet-
Congrats to @SimranArjani for leading this important project @Rutgers_NJMS @NJMSDeptSurgery #TJBostonian @Vishnu__Prasath @PatrickLQuinn @OhioStateSurg #costeffectiveness https://t.co/5HHS7eki0r
-
-
Mashup Score: 2Cost-Utility Analysis of Thumb Carpometacarpal Resection Arthroplasty: A Health Economic Study Using Real-World Data - 2 year(s) ago
Knowledge about the costs and benefits of hand surgical interventions is important for surgeons, payers, and policy makers. Little is known about the cost-effectiveness of surgery for thumb carpometacarpal osteoarthritis. The objective of this study was to examine patients’ quality of life and economic costs, with focus on the cost-utility ratio 1 year after surgery for thumb carpometacarpal…
Source: Journal of Hand SurgeryCategories: Latest Headlines, RheumatologyTweet-
#VisualAbstract: #CostUtility Analysis of #ThumbCarpometacarpal Resection #Arthroplasty: A Health Economic Study Using Real-World Data @SchulthessNews @ZHAW #CostEffectiveness #thumb #osteoarthritis #HandSurgery #QualityOfLife https://t.co/Ju2HB35Okt https://t.co/PX2DFYYye7
-
-
Mashup Score: 0
Cost incurred for stage I gastric cancer (GC) was €22 434 €23 498, stage III €22 445, and stage IV €22 032. Based on these values, the cost per quality adjusted
Source: OUP AcademicCategories: Latest Headlines, SurgeryTweet-
This paper uses real world data to explore #costeffectiveness of #surgery vs #supportivecare for #gastriccancer. Surgery offers good value #qalys #some4surgery #openaccess @SEIQuirurgica @asgbi @SocSARS https://t.co/1Bs6arAefV https://t.co/qu8oonAKZB
-
Dr Ruben Mesa shares invaluable insights on addressing the critical challenges in health care today. Access to innovative therapies for #rarecancers is a top priority. Check out the interview: https://t.co/8bD0XLc1RD #RareCancers #Healthcare #TreatmentAccess #CostEffectiveness https://t.co/J5eT1DnYld